Sun Pharma's $13 Billion Bid Sends Organon & Co. Surging 31%
NEW YORK, April 24 —
Organon & Co. (OGN) jumped roughly 31% to $11.26 after reports that Sun Pharmaceutical made a $13 billion takeover bid.
- OGN surged ~31% on reported $13bn Sun Pharma acquisition offer
- Stock trades at 3.1x forward P/E on $6.2bn TTM revenue, even after the pop
- Evercore ISI flags the report as unconfirmed and speculative. No official statement from either company
What Actually Happened
Reports surfaced that Sun Pharma, India's largest pharmaceutical company by market cap, offered $13 billion to acquire Organon, the women's health and biosimilars business Merck spun off in 2021. The stock ripped higher. But that $13 billion number needs context. Organon carries a heavy debt load from the spinoff, and the $13bn figure almost certainly represents enterprise value — not what shareholders would pocket. Subtract the debt and the equity check shrinks fast. Even after a 31% move, OGN's market cap sits around $2.9bn. The gap between $2.9bn and $13bn is mostly leverage, not premium.
The Catch
This is a rumor, not a deal. Evercore ISI explicitly notes the talks lack confirmation and remain speculative. Organon has said nothing. Sun Pharma has said nothing. Anyone who bought at $11.26 on a headline risks the next headline reading "Sun Pharma denies bid." There's also a financing question. Sun Pharma's own market cap hovers around $45bn. A $13bn acquisition would be the largest outbound pharma deal from India. Lenders would need convincing that Organon's declining Nexplanon exclusivity and biosimilar pricing pressure are worth that bet.
Bottom Line
The valuation tells a story on its own. Even after surging 31%, Organon trades at 3.1x forward earnings on $6.2bn in revenue. That is extraordinarily cheap for a pharma company with real products and real cash flow. The stock was priced for distress before this rumor — and the bid, if real, suggests someone else sees it the same way. If the deal dies, OGN probably gives back most of the move. If it's real, there's likely more from here, because no acquirer opens at their best price. The only data point that matters now is an official statement from either company.
For a full financial breakdown of Organon, generate a free report at basisreport.com/stock/ogn.
Basis Report does not hold positions in securities discussed. This is not investment advice.